We make biomedical knowledge actionable. For doctors, patients, and companies. We make precision medicine a reality Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the field of in-silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support tools. They are used where precision medicine patient care or efficient drug development require increasingly complex data interpretations.
At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, as well as software development work on making Big Data usable for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements.
Molecular Health’s solutions make it possible to convert large volumes of data into evidence-based, medically relevant results for healthcare professionals. We provide molecular pathologists, human geneticists, physicians, and patients with better information about diagnoses and treatment options.
By optimizing clinical studies based on AI techniques, we support pharmaceutical and health organizations in developing active substances and powerful disease models.
Fact sheet Molecular Health
Molecular Health is a portfolio company of dievini Hopp Biotech Holding (www.dievini.de).
1/4
CU RA
RT
E
KNOWLEDGE
ONTENT DC TE
Dr. Friedrich von Bohlen, CEO Molecular Health
G LIN E OD
A
The foundation of our products and solutions is the Dataome technology, which we have developed and built over more than a decade and has been constantly updated since then. Dataome is one of the largest digital platforms for biomedical information, harnessing the knowledge that is growing daily around the world for patient care, research, and new drug development.
M
Dataome – one of the largest and most comprehensive biomedical databases in the world.
IFI
CIA L
IN T E L L
“As a pioneer in the realization of precision medicine, we ensure that available clinical and molecular knowledge is made accessible and usable for daily patient care. This makes us the ideal partner for innovative physicians, researchers, and developers.”
Dr. Stephan Brock, Managing Director and CTO Molecular Health
Fact sheet Molecular Health
N IGE
C
“The combination of IT and molecular biology will bring about some of the greatest medical advances in the coming years. With Dataome, Molecular Health is a trailblazer in this field, offering unique software solutions that make better medicine possible.”
2/4
Facts & figures Year of founding 2004 Head office
Molecular Health GmbH, Germany
Management
Friedrich von Bohlen, PhD Stephan Brock, PhD
Investors dievini Hopp BioTech, investment vehicle of the founder and former chairman of SAP, Dietmar Hopp Locations Molecular Health, Inc. US corporate office, Boston, MA, USA Business segment
Computer-aided, data-driven precision medicine/biomedicine
Products Registered as an IVD medical device in the EU, MH Guide helps molecular pathologists and oncologists in the clinical annotation of gene variants to help physicians make precision oncology decisions. The customizable software application provides access to data from one of the world’s largest knowledge bases of biomedical information for results aligned with the current state of science. MH Guide/BRCA assists human geneticists in identifying and reporting clinically significant germline variants associated with hereditary breast and ovarian cancer (HBOC) syndrome. MH Guide/BRCA is part of the EU-approved IVD software MH Guide.
Fact sheet Molecular Health
3/4
MH Guide/Mendel supports human geneticists in identifying clinically significant genetic variants and preparing a diagnostic report for the patient. MH Guide/Mendel is part of the EU-approved IVD software MH Guide. MH Predict is a software solution that helps drug and biotech companies manage risks in drug research and development. Using artificial intelligence (AI) and machine learning (ML), the application helps to estimate the likelihood of success of study programs, identify and optimize parameters critical to success, and identify medical innovations from a range of promising compounds at an early stage. MH Insilico is a service that helps research institutions and drug manufacturers develop disease models to identify targets for new drugs. The mechanisms of action of these drugs can be simulated at the molecular level with MH Insilico. This provides data-based evidence of the potential of medical innovations, enabling them to be identified at an early stage and successfully marketed. MH Effect is an application that combines clinical and molecular data to simulate and analyze drug-drug interactions. Researchers or regulatory authorities can thus accurately assess the safety profile of a drug even before in vivo testing. The technology can also identify potentially effective or more tolerable new drug combinations for combating diseases and support drug manufacturers in their search for new treatment options. Employees
124 (as at January 2021)
Customers Among others, FDA, SAP, Charité Berlin, Karolinska Institute, Riken Genesis, MD Anderson Cancer Center, Johns Hopkins University, Agena Bioscience, dkfz, University of Heidelberg, as well as asset management firms such as Daten Capital LLP
Press contact Thomas König Head of Marketing & PR Phone +49 6221 43851-2280 • thomas.koenig@molecularhealth.com
Fact sheet Molecular Health
MH-20-067-1 EN
Memberships/organizations BIO Deutschland, DKG (German Cancer Society), BvMed (Federal Association of Medical Technology), Gesundheitsstadt Berlin, DGIM (German Society of Internal Medicine), GfH (German Society of Human Genetics), VDGH (Association of the Diagnostics Industry), PMC (Personalized Medicine Coalition)
molecularhealth.com
4/4